血液透析联合腹膜透析治疗终末期肾脏病的临床疗效

Clinical observation of hemodialysis combined with peritoneal dialysis in the treatment of end-stage renal disease

目的探讨血液透析(HD)联合腹膜透析(PD)治疗终末期肾脏病(ESRD)的临床疗效。方法选取2016年8月至2019年8月营口市中心医院收治的126例终末期肾脏病患者作为研究对象,采用随机分组法分为联合组、HD组与PD组,每组42例。联合组采用PD+HD治疗,HD组采用HD治疗,PD组采用PD治疗。比较3组治疗1年后不良事件发生率、生存率及生命质量。结果联合组不良事件总发生率为9.52%,低于HD组的28.57%及PD组的50.00%,且HD组低于PD组,差异有统计学意义(P<0.05);联合组生存率为95.24%,高于HD组的76.19%及PD组的73.81%,差异有统计学意义(P<0.05);HD组与PD组生存率比较差异无统计学意义;联合组社交质量、工作状况、日常生活、精神状况、性功能评分均高于HD组、PD组,且HD组高于PD组,差异有统计学意义(P<0.05)。结论血液透析联合腹膜透析治疗终末期肾脏病效果显著,改善患者生命质量,提高生存率,降低不良事件发生风险,值得临床推广应用。

Objective To investigate the clinical efficacy of combined use of peritoneal dialysis(PD)and hemodialysis(HD)in the treatment of end-stage renal disease(ESRD).Methods 126 patients with end-stage renal disease admitted to Yingkou Central Hospital from August 2016 to August 2019 were selected as the study subjects,and they were randomly divided into the combination group,the HD group and the PD group,with 42 cases in each group.The combination group was treated with PD+HD,the HD group was treated with HD,and the PD group was treated with PD,the incidence of adverse events,survival rate and quality of life were compared among the three groups after one year of treatment.Results The incidence of adverse events in the combined group was 9.52%,which was lower than 28.57%in the HD group and 50.00%in the PD group,and the HD group was lower than the PD group,the differences were statistically significant(P<0.05);the survival rate in the combined group was 95.24%,which was significantly higher than 76.19%in the HD group and 73.81%in the PD group,and the differences were statistically significant(P<0.05);there was no significant difference in survival rate between HD group and PD group;the scores of social quality,work status,daily life,mental status,sexual function in the combined group were significantly higher than those in the HD group and the PD group,and the HD group were higher the PD group,and the differences were statistically significant(P<0.05).Conclusion Hemodialysis combined with peritoneal dialysis has significant efficacy in the treatment of end-stage renal disease,improving the quality of life of patients,increasing the survival rate and reducing the risk of adverse events,it is worthy of clinical promotion and application.